
Why Gene Therapy Manufacturing Fails FDA
transcript
show notes
Why do even the most revolutionary gene therapies with promising clinical results face critical roadblocks on their path to commercial approval? In this episode of the DDReg Knowledge Capsule, we delve deep into the core reasons behind Biologics License Application (BLA) delays, focusing on common Chemistry, Manufacturing, and Controls (CMC) pitfalls, weak analytical strategies, and limited comparability data.We unpack the regulatory expectations of the FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Therapeutic Products (OTP), highlighting why early regulatory alignment, rigorous product characterisation, and proven manufacturing consistency are absolutely vital for success. Whether you are navigating vector-related complexities, scale-up challenges, or preparing for critical pre-BLA meetings, this episode provides the strategic insights needed to ensure your manufacturing, clinical, and quality teams are fully aligned for FDA readinessRead this Blog: https://resource.ddregpharma.com/blogs/gene-therapy-bla-submission-regulatory-strategy/